Logo - springer
Slogan - springer

Biomedical Sciences - Cancer Research | Evolution-adjusted Tumor Pathophysiology: - The Novel Language of Tumor Biology

Evolution-adjusted Tumor Pathophysiology:

The Novel Language of Tumor Biology

Reichle, Albrecht (Ed.)

2013, X, 453 p. 95 illus., 87 illus. in color.

Available Formats:

Springer eBooks may be purchased by end-customers only and are sold without copy protection (DRM free). Instead, all eBooks include personalized watermarks. This means you can read the Springer eBooks across numerous devices such as Laptops, eReaders, and tablets.

You can pay for Springer eBooks with Visa, Mastercard, American Express or Paypal.

After the purchase you can directly download the eBook file or read it online in our Springer eBook Reader. Furthermore your eBook will be stored in your MySpringer account. So you can always re-download your eBooks.


(net) price for USA

ISBN 978-94-007-6866-6

digitally watermarked, no DRM

Included Format: PDF and EPUB

download immediately after purchase

learn more about Springer eBooks

add to marked items


Hardcover version

You can pay for Springer Books with Visa, Mastercard, American Express or Paypal.

Standard shipping is free of charge for individual customers.


(net) price for USA

ISBN 978-94-007-6865-9

free shipping for individuals worldwide

usually dispatched within 3 to 5 business days

add to marked items

  • Applied systems biology
  • Personalizing tumor therapy with novel methodological approaches
  • Drafting the non-genomic counterpart of the genome: Rationalizations constituting tumor-associated normative notions (angiogenesis, inflammation, immune response etc.)
  • Reconstructing and operationalizing starting points for an evolution theory
  • Evolution-adjusted tumor pathophysiology as novel clinical and pharmaceutical technology for bioengineering tumor response
Combined modularized therapies for metastatic cancer are pointing to central problems of communication among ‘systems participators’. A communication theory explains 'social engineering', endogenously induced or by implementing non-normative boundary conditions. Evolution-adjusted tumor pathophysiology is borne by an evolution theory, which contrasts narrative evolution histories. The tool of rationalizations constituting the tumor's normativity (inflammation, immune response etc.) represents the non-genomic counterpart of the tumor genome and should be additionally assessed during tumor staging. Evolution-adjusted tumor pathophysiology allows implementing applied systems biology, a novel clinical and pharmaceutical technology for bioengineering tumor response and personalizing tumor therapy. Combined modularized therapy, evolution-adjusted tumor pathophysiology, and ‘universal’ biomarkers concertedly address genetically based tumor heterogeneity.

Content Level » Professional/practitioner

Keywords » Biomodulatory tumor therapy - Communication theory - Evolution theory - Philosophy - Tumor pathophysiology

Related subjects » Biomedical Sciences - Cancer Research - Pharmacology & Toxicology

Table of contents 

Preface. I  Introduction. 1. Communication ─ evolution ─ pathophysiology: An endogenous conjunction ─Instead of an introduction. II  Combined modularized therapies for metastatic tumors: Pointing to central problems of communication among ‘systems participators’ in tumors. 2 Applied systems biology for the control of metastatic cancer: Therapeutic top-down strategy for targeting the tumors’ normativity. 3 Targeting the proangiogenic network in angiosarcomas: Biomodulatory therapy.4 Long-term results of combined modularized, immune-modulatory, angiostatic, and antiinflammatory therapy in systemically pre-treated multi-systems Langerhans cell histiocytosis. 5 Redirecting and modulating rationalizations of tumor-immanent normative functions in castration-resistant prostate ancer. III  Social engineering: Biomodulation, either endogenously initiated or by implementation of non-normative boundary conditions. 6 Non-hierarchically organized operations in malignancies: Stromal dysfunction induces hematopoetic malignancies. 7 Biomodulatory therapy approaches in renal clear cell carcinoma: A perspective. 8 Proteome analysis identified the PPARc ligand 15d-PGJ2 as a novel drug inhibiting melanoma progression and interfering with tumor-stroma interaction.IV   The tumors’ normativity: Reconstructing and operationalizing starting  points for an evolution theory. 9  The philosophical quest of a cancer cell: Redefining existentialism. 10 The tumor’s normativity: Normative structures, action norms and decision maxims as therapeutic targets for tumor therapy. 11 Criticizable claims for the validity of communication acts in biological systems: Therapeutic implications in cancer. V   Evolution theory. 12 Evolution theory: Its practical relevance for understanding tumor development and specifying tumor therapy. 13 Modularity, subjectivity, intersubjectivity and normativity: Clinically applicable operative benchmarks.14 Turning upside down the mode of science to emphasize and harness the impact of environmental communicative events. VI   From genome- or organ-centric to rationalization-centric systematization of tumors. 15 Purposive-rational tumor therapy: Exploiting the tumor’s ‘living world’ for diversifying, specifying and personalizing tumor therapy. 16 Including rationalizations of tumor-associated normative notions in pathophysiologic considerations: Communication-theoretical implications.VII  Reconstruction of tumor-immanent normative functions, structures and decision maxims (hubs). 17 Bridging a diagnostic and therapeutic gap: Selecting, assessing and categorizing tumor-associated normative notions. 18 Personalizing tumor pathophysiology by diagnosing developmental problems in tumors with imaging techniques. 19  Biologic memory: Induction by metronomically administered combined modularized therapy. VIII The tool of rationalizations constituting tumor-associated normative notions: The non-genomic counterpart of the tumor genome and therefore, an important therapeutic target for diversifying palliative care. 20  Diversifying and specifying palliative care for patients with metastatic cancer by therapeutic implementation of non-normative boundary conditions. 21 Targeting a hallmark of cancer: Simultaneous inflammation and tumor control for palliative care in metastatic cancer. IX  Novel clinical and pharmaceutical technology for bioengineering tumor response. 22 Combined modularized tumor therapy ─ tumor biology ─ and prognostic factors: Bioengineering tumor response. X   Objectifying the systems objects’ subjectivity in biological systems: A novel reification of the scientific picture about the ‘objective’ world. 23 The systems objects’ subjectivity as scientific object. Index.

Popular Content within this publication 



Read this Book on Springerlink

Services for this book

New Book Alert

Get alerted on new Springer publications in the subject area of Cancer Research.